Skip to main content

Table 2 Adverse events with an incidence >5 % of patients in any dose group [17]

From: The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials

Adverse event

Placebo (%)

Lasmiditan 100 mg (%)

Lasmiditan 400 mg (%)

Dizziness

1

28

37

Fatigue

2

21

24

Vertigo

1

15

24

Somnolence

2

12

11

Paraesthesia

2

11

20

Heaviness

1

5

7

Nausea

0

11

7

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us